2SHB 1745: Improving diversity in clinical trials.

What this bill does

Requires the University of Washington, Washington State University, and any hospital or state agency that receives National Institutes of Health Funding for drug and medical device clinical trials to adopt a policy for recruiting members of underrepresented demographic groups to participate in the clinical trial. Codifies the Washington State Institutional Review Board (Review Board). Requires the Review Board and the Andy Hill Cancer Research Endowment to consider in their evaluation four factors related to increasing participation of underrepresented communities in clinical trials.

From the Washington State Legislature's nonpartisan staff bill analysis. Read the full analysis ↗

Floor votes

• House: 3rd Reading & Final Passage · March 6, 2023
  95 yea · 0 nay · 3 not voting
• House: Final Passage as Amended by the Senate · April 19, 2023
  98 yea · 0 nay
• Senate: 3rd Reading & Final Passage as Amended by the Senate · April 12, 2023
  49 yea · 0 nay

Track 2SHB 1745 on OlympiaTrack

A free account adds the full hearing and amendment record, who testified, roll calls by member, and a list to track it on. Paid plans add a plain-English AI summary and email alerts when this bill moves.

Other bills sponsored by Thai

• HB 1021: Aligning social worker licensing requirements.
• SHB 1074: Addressing documentation and processes governing landlords' claims for damage to residential premises.
• SHB 1077: Concerning courthouse facility dogs.
• SHB 1079: Concerning rapid whole genome sequencing.
• SHB 1275: Concerning athletic trainers.